Navigation Links
Helix BioPharma Corp. Announces Fiscal 2009 Results
Date:10/29/2009

Product revenue in fiscal 2009 totalled $3,244,000 and represents an increase of $292,000 or 9.9% when compared to product revenue in fiscal 2008 of $2,952,000. Product sales of Orthovisc® grew in fiscal 2009 while Klean-Prep(TM) revenue remained relatively stable. License fees and royalties in fiscal 2009 totalled $597,000 and represent a decrease of $42,000 or 6.6% when compared to fiscal 2008. The decrease reflects lower Klean-Prep(TM) royalty revenue from Helsinn-Birex which was offset by the final payment from Lumera Corporation of US$75,000 when it provided the Company with notice of termination of its sub-license agreement.

Cost of sales in fiscal 2009 and 2008 totalled $1,516,000 and $1,239,000, respectively. As a percentage of product revenues, cost of sales in fiscal 2009 and 2008 were 46.7% and 42.0%, respectively. In addition to some foreign exchange impact, cost of sales was also impacted by higher distribution costs. The increase in cost of sales, on a percentage, basis was mainly the result of lower average selling price per units sold of Orthovisc®. Lower pricing was offered on Orthovisc® to assist in customer retention for a scheduled launch of a new, single injection product in the first quarter of fiscal 2010.

Research and development expenditures in fiscal 2009 totalled $10,322,000 and represent an increase of $5,258,000 or 103.8% when compared to fiscal 2008. L-DOS47 and Topical Interferon Alpha-2b reflect an increase of 52.6% and 171.2%, respectively. The increase in research and development expenditures associated with L-DOS47, are primarily related to the scale-up manufacturing program and ongoing collaborative research initiatives in anticipation of furnishing product for future clinical testing. The increase in research and development expenditures associated with Topical Interferon Alpha-2b reflect the ongoing costs for the AGW Phase II clinical trial in Sweden and Germany in addition to scale-u
'/>"/>

SOURCE Helix BioPharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Helix BioPharma Provides Updates on Topical Interferon Alpha-2b and L-DOS47 Following Pre-IND Meetings With the U.S. FDA
2. J. Craig Venter, Ph.D. Receives Double Helix Medal from Cold Spring Harbor Laboratory
3. Helix Receives Approval to Open Sites in Germany for its Ongoing Clinical Trial With Topical Interferon Alpha-2b in Patients With Ano-Genital Warts
4. China Biopharmaceuticals Holdings, Inc. Shareholders Overwhelmingly Support Merger with NeoStem, Inc., a NYSE AMEX Listed Company Trading Under Symbol NBS
5. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentation of Zerenex (ferric citrate) for the Treatment of Hyperphosphatemia at the Upcoming American Society of Nephrology Renal Week Meeting in San Diego
6. NGM Biopharmaceuticals Appoints Dr. Arthur D. Levinson, Former Genentech CEO, to its Board of Directors
7. Laureate Pharma Announces Signing New Biopharmaceutical Development & Manufacturing Agreement
8. PDL BioPharma Completes October 1 Special Dividend Payment
9. DOR BioPharma Announces Private Equity Financing of $3.85 Million with its Partner Sigma-Tau and Other Institutional Investors
10. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
11. DOR BioPharma Announces NIH Grant Award to Support Phase 1/2 Clinical Trial of DOR201 in Radiation Enteritis

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2009)...ARK, Ill., Nov. 19 The ... as one of its Most Admired Corporate Dealmakers f...d Abbott as its Most Admired Dealmaker in pharma/b...uisitions and divestitures since January 2006. ,...usiness portfolio with a focus on high-growth, inn...
(Date:11/19/2009)...of International Internet Week of Action ,, SI...-- The U.S. Food and Drug Administration today com...rt, called the International Internet Week of Acti...ing medical products. ,, (Logo: http://www.new...ing the effort, the FDA,s Office of Criminal Inves...
(Date:11/19/2009)...ON, N.J., Nov. 19 Impliant, Inc., ...o traditional spinal fusion surgery, announced tod...anagement team as the Vice President of Clinical a...w.newscom.com/cgi-bin/prnh/20080527/NETU060LOGO ...regulatory experience in the spinal and medical de...
Breaking Medicine Technology:The Deal Names Abbott Top Dealmaker for Second Consecutive Year 2The Deal Names Abbott Top Dealmaker for Second Consecutive Year 3UPDATE: FDA Issues 22 Warning Letters to Web site Operators 2Impliant Announces the Addition of Vice President of Clinical and Regulatory Affairs to Executive Management Team 2Impliant Announces the Addition of Vice President of Clinical and Regulatory Affairs to Executive Management Team 3Mobile MedCheck Brings Back House Calls 54959 1Mobile MedCheck Brings Back House Calls 54959 2Mobile MedCheck Brings Back House Calls 54959 3Mobile MedCheck Brings Back House Calls 54959 4Angiotech Pharmaceuticals announces the commercial launch of the Option 28TM 29 Inferior Vena Cava Filter in the United States 13637 1Angiotech Pharmaceuticals announces the commercial launch of the Option 28TM 29 Inferior Vena Cava Filter in the United States 13637 2Angiotech Pharmaceuticals announces the commercial launch of the Option 28TM 29 Inferior Vena Cava Filter in the United States 13637 3Angiotech Pharmaceuticals announces the commercial launch of the Option 28TM 29 Inferior Vena Cava Filter in the United States 13637 4Angiotech Pharmaceuticals announces the commercial launch of the Option 28TM 29 Inferior Vena Cava Filter in the United States 13637 5Impax Pharmaceuticals Selects OmniComm Systems to Provide eClinical Solutions for International Phase III Study in Parkinsons Disease 4874 1Impax Pharmaceuticals Selects OmniComm Systems to Provide eClinical Solutions for International Phase III Study in Parkinsons Disease 4874 2Impax Pharmaceuticals Selects OmniComm Systems to Provide eClinical Solutions for International Phase III Study in Parkinsons Disease 4874 3
...ree Oritavancin Studies Presented at ECCMID/ICC, M...ganta,Therapeutics today announced results from tw...cin to stop bacterial growth in vitro,when tested ...ne,study demonstrating the activity of oritavancin...ia. Oritavancin, a novel,lipoglycopeptide antibiot...
...istorical Analyses Help Plan for Future Pandemics ...tent riddles of the,deadly 1918 Spanish influenza ...rying severity. Why were some municipalities such ...s like Philadelphia,when both implemented similar ...according to two independent studies funded by the...
Other Medicine Technology:Targanta Reports Improved Ability of Oritavancin to Stop Bacteria,Growth In Vitro Compared With Other Glycopeptide Antibiotics 2Targanta Reports Improved Ability of Oritavancin to Stop Bacteria,Growth In Vitro Compared With Other Glycopeptide Antibiotics 3Targanta Reports Improved Ability of Oritavancin to Stop Bacteria,Growth In Vitro Compared With Other Glycopeptide Antibiotics 4Targanta Reports Improved Ability of Oritavancin to Stop Bacteria,Growth In Vitro Compared With Other Glycopeptide Antibiotics 5Targanta Reports Improved Ability of Oritavancin to Stop Bacteria,Growth In Vitro Compared With Other Glycopeptide Antibiotics 6Rapid Response was Crucial to Containing the 1918 Flu Pandemic 2Rapid Response was Crucial to Containing the 1918 Flu Pandemic 3Rapid Response was Crucial to Containing the 1918 Flu Pandemic 4Rapid Response was Crucial to Containing the 1918 Flu Pandemic 5
(Date:11/21/2009)..., , WASHINGTON, Nov. 21 /PRNewswire-USNew...90s to eliminate onchocerciasis (river blindness) ...alence of the disease in recent years, as evidence...equiring mass drug administration in six endemic c... annual meeting of the American Society of Tropica...
(Date:11/21/2009)... HAPPYneuron,s most popul...e on the iPhone and iPod Touch. , ...09 -- HAPPYneuron,s most popular and addictive gam...iPod Touch. Split Words is designed to help banish...he SplitWords iPhone brain game challenges the b...
(Date:11/20/2009)..., , PRINCETON, NJ, Nov. 20 /PRNewswire-Fir...today that a Special Meeting of Shareholders will ...of the Meeting is to consider approval of two spec...o approve and authorize the sale of all or substan... on the terms provided for in the asset purchase a...
(Date:11/20/2009)..., , MADISON, N.J., Nov. 20 /PRNewswire-F...nfluenza virus may have peaked in late October, bu...al source of illness in all age groups, including ...agnostics Incorporated (NYSE: DGX ), the world,s...on and services. ,, In its most recent Quest D...
(Date:11/20/2009)..., , LAS VEGAS, Nov. 20 /PRNewswire-USNewswir...y, Executive Director of the Nevada Health Care As...on (NHCA) commends and thanks Senate Majority Lead...ion a step closer toward our goal of protecting ev...ing home care, and preserving the strength and via...
Breaking Medicine News(10 mins):Health News:River Blindness (Onchocerciasis) Reduced By Nearly One-Third In At-Risk Populations In Six Countries 2Health News:River Blindness (Onchocerciasis) Reduced By Nearly One-Third In At-Risk Populations In Six Countries 3Health News:River Blindness (Onchocerciasis) Reduced By Nearly One-Third In At-Risk Populations In Six Countries 4Health News:HAPPYneuron releases iPhone Brain Game 2Health News:HAPPYneuron releases iPhone Brain Game 3Health News:NUCRYST Announces Special Meeting of Shareholders 2Health News:NUCRYST Announces Special Meeting of Shareholders 3Health News:H1N1 Pandemic May Have Peaked in October in U.S., According to Quest Diagnostics 2Health News:H1N1 Pandemic May Have Peaked in October in U.S., According to Quest Diagnostics 3
...n in people with diabetes than in those without th...sue of Archives of Ophthalmology , one of the JA...ion Americans had diagnosed diabetes mellitus in 2...ls with diagnosed diabetes will increase to 48.3 m...
... ,can,t remember anything, study says , , ...k may do more than help guide your daily sleep/wak...ng and memory, say Stanford University researchers...ut it, they "can,t remember anything," said lead a...
... on October 30 - - Presentation at Oppenheimer,s ... November 4 -, - Annual Analyst Day...s on November 7 -, S...Probe will release its third quarter 2008 financia...
...nal study Study needed because of low cardia...Advanced Circulatory Systems,Inc. ( http://www.adv...,received an additional $1.5 million in funding fr...a hospital. Oshkosh is one,of six sites included i...
...t Rights Management System, Supports Global Pharm...d, WEST CHESTER, Pa., Oct. 13 Modevity, LLC anno...anufacturer has integrated,Modevity,s Imperium tec...eo content. Imperium is applied to this,new medica...
...RT WORTH, Texas, Oct. 13 The Dannon Company, Inc.... the Will Rogers Memorial,Center. The company, whi...,out thousands of bottles of free Dannon smoothies...s about their food choices,to ensure a healthy fut...
Other Medicine News:Health News:Vision loss more common in people with diabetes 2Health News:Circadian Rhythm Plays Role in Memory 2Health News:Gen-Probe Announces Webcasts of Three Upcoming Investor Events 2Health News:Gen-Probe Announces Webcasts of Three Upcoming Investor Events 3Health News:Advanced Circulatory Systems Receives $1.5 Million From NIH for Study of Cardiac Arrest Resuscitation Techniques 2Health News:Global Pharma Integrates Imperium(TM) to Support Launch Content ROI Initiatives! 2Health News:The Dannon Company Sponsors FitFuture KIDS Fest 2Health News:The Dannon Company Sponsors FitFuture KIDS Fest 3
... ARUP Laboratories is a national reference laborat...y research and development. ARUP offers an extensi...tests in clinical and anatomic pathology. Owned by...s include more than half of the nation's universit...
... ARUP Laboratories is a national reference laborat...y research and development. ARUP offers an extensi...tests in clinical and anatomic pathology. Owned by...s include more than half of the nation's universit...
... ARUP Laboratories is a national reference laborat...y research and development. ARUP offers an extensi...tests in clinical and anatomic pathology. Owned by...s include more than half of the nation's universit...
... ARUP Laboratories is a national reference laborat...y research and development. ARUP offers an extensi...tests in clinical and anatomic pathology. Owned by...s include more than half of the nation's universit...
Medicine Products: